Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics

Executive Summary

The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.

Advertisement

Related Content

Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
CVS Launching Program To Exclude New Drugs Deemed Not Cost Effective
Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel